HomeABCL • NASDAQ
add
AbCellera Biologics Inc
Previous close
$3.85
Day range
$3.92 - $4.20
Year range
$3.62 - $8.05
Market cap
1.18B USD
Avg Volume
1.15M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | 9.18M | -57.40% |
Operating expense | 170.49M | 62.87% |
Net income | -47.15M | -57.73% |
Net profit margin | -513.67 | -270.21% |
Earnings per share | -0.16 | -60.00% |
EBITDA | -58.52M | -143.91% |
Effective tax rate | 2.99% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 760.58M | -14.20% |
Total assets | 1.49B | -3.43% |
Total liabilities | 335.78M | 9.15% |
Total equity | 1.15B | — |
Shares outstanding | 292.78M | — |
Price to book | 0.97 | — |
Return on assets | -11.01% | — |
Return on capital | -13.25% | — |
Cash Flow
Net change in cash
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -47.15M | -57.73% |
Cash from operations | -19.61M | -163.44% |
Cash from investing | -24.32M | -42.55% |
Cash from financing | 3.76M | 978.80% |
Net change in cash | -39.10M | -368.51% |
Free cash flow | 309.88K | -99.21% |
About
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
CEO
Founded
2012
Headquarters
Website
Employees
586